Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
— California, December 2021–May 2022 | MMWR Skip directly to site content Skip directly to …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United
States, April–September 2022 - PMC Back to Top Skip to main content NIH NLM Logo Access …

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Pfizer's oral antiviral drug paxlovid significantly reduces hospital admissions and deaths
among people with covid-19 who are at high risk of severe illness, when compared with …

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

Racial and Ethnic Disparities in Outpatient Treatment of COVID-19 ― United States, January–July
2022 | MMWR Skip directly to site content Skip directly to search Español | Other Languages …